八方同创新兽药证书获批：鸭肝炎双价疫苗创新突破

八方同创（BIOPHARMAVET）旗下联合研发的鸭病毒性肝炎二价活疫苗（1型BJ80株+3型HB80株）获得国家三类新兽药注册证书，可同时防控1型和3型鸭病毒性肝炎，为水禽养殖提供更稳定的免疫保护。

八方同创（BIOPHARMAVET）旗下上海创宏生物科技有限公司与龙阔（苏州）生物工程有限公司联合研发的“鸭病毒性肝炎二价活疫苗（1型BJ80株+3型HB80株）”获得国家三类新兽药注册证书。该产品可同时覆盖鸭病毒性肝炎1型和3型主流毒株，为雏鸭养殖提供更全※面 的免疫保护，进一步体现公司在畜禽疫病防控领域的研发实力。

喜报｜再添硕果！八方同创斩获第6个国家新兽药证书Milestone | Biopharmavet Earns Its 6th National New Veterinary Drug Registration Certificate热烈祝贺！八方同创旗下上海创宏生物科技有限公司与龙阔（苏州）生物工程有限公司联合研发的鸭病毒性肝炎二价活疫苗（1型BJ80株+3型HB80株），成功获得国家三类新兽药注册证书，新兽药证书号：（2026）新兽药证字120号。We are delighted to announce that the Duck Viral Hepatitis Bivalent Live Vaccine (Type 1 BJ80 Strain + Type 3 HB80 Strain), jointly developed by Shanghai Chuanghong Biotechnology Co., Ltd. and Longkuo (Suzhou) Bioengineering Co., Ltd., both under Biopharmavet, has been officially granted a National Class III New Veterinary Drug Registration Certificate (No. (2026) New Veterinary Drug Cert. 120).行业痛点：单一血清型疫苗难以应对混合流行The Industry Challenge鸭病毒性肝炎是危害雏鸭养殖的核※心烈性传染病。当前养殖环境中1型、3型毒株混合流行、交叉感※染问题突出，传统单一血清型疫苗防护覆盖有限，极易造成雏鸭大规模发病、死亡，严重影响养殖效益。Duck viral hepatitis remains one of the most damaging acute infectious diseases in duckling production. With Type 1 and Type 3 strains co-circulating and cross-infecting on many farms, conventional single-serotype vaccines offer limited coverage, often leading to widespread illness and high mortality, and significantly hurting farm profitability.一针双防：同时覆盖1型、3型主流毒株Dual Protection in One Shot本次获批的二价活疫苗创新搭载1型BJ80株+3型HB80株双毒株配方，精※准覆盖田间主流流行毒株，有效解决单一疫苗防护不全、防控效果差的行业难题。产品防护范围广、安全性高、免疫效果稳定，全※方位 筑牢雏鸭养殖防疫屏障，为规模化水禽养殖保驾护航。The newly approved bivalent live vaccine combines the Type 1 BJ80 strain and the Type 3 HB80 strain to precisely target the predominant field strains. It addresses the long-standing limitation of incomplete protection from single vaccines. With broad protection, high safety and stable immune response, it builds a comprehensive biosecurity barrier for duckling production and supports large-scale waterfowl farming.匠心研发·持续创新R&D-Driven, Innovation-Continuous此次新兽药证书的成功获批，是八方同创在研发实力、产品质量与技术创新方面再次获得国※家级权威认证，标志着公司在畜禽疫病防控、水禽动保研发领域实现又一次跨越式突破。

未来，八方同创将持续深耕畜禽动物疫病防控领域，以更优※质、更精※准、更前沿的动保产品，助力养殖业降本增效、安全稳产、健康发展。This approval is another authoritative national recognition of Biopharmavet's R&D capabilities, product quality and technological innovation, marking a further breakthrough in livestock disease control and waterfowl animal health solutions.

Looking ahead, Biopharmavet will continue to focus on animal disease prevention and control, delivering higher-quality, more precise and more advanced animal health products to help the farming industry reduce costs, improve efficiency and grow sustainably.深耕动保创新，守护养殖未来！八方同创，始终在路上！Innovating in animal health, safeguarding the future of farming.Biopharmavet — always on the move.